BBFA
GILD icon

Brindle & Bay Financial Advisors’s Gilead Sciences GILD Stock Holding History

Brindle & Bay Financial Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$947K Buy
7,495
+1,604
+27% +$211K 0.47% 45
2026
Q1 		$821K Sell
5,891
-151
-2% -$21.1K 0.5% 41
2025
Q4 		$742K Buy
+6,042
New +$734K 0.49% 39

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brindle & Bay Financial Advisors's GILD Position: Q2 2026 in Review

Brindle & Bay Financial Advisors increased its Gilead Sciences (GILD) stake by 27% in Q2 2026, buying an estimated $211K and bringing the position to 7,495 shares worth $947K. The position accounts for 0.47% of the portfolio, ranked #45.

Brindle & Bay Financial Advisors first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. 2,261 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Brindle & Bay Financial Advisors held 7,495 shares of Gilead Sciences worth $947K as of Q2 2026.
  • Brindle & Bay Financial Advisors bought 1,604 Gilead Sciences shares in Q2 2026, an estimated $211K.
  • Gilead Sciences made up 0.47% of Brindle & Bay Financial Advisors's portfolio in Q2 2026, its #45 holding.
  • Brindle & Bay Financial Advisors first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • 2,261 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Brindle & Bay Financial Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.